Cipla Limited — Imatinib Exporter Profile
Indian Pharmaceutical Exporter · #1 for Imatinib · $5.2M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Imatinib with $5.2M in export value and 103 verified shipments. Cipla Limited holds a 17.6% market share in Imatinib exports across 8 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Imatinib Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Imatinib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PAKISTAN | $1.7M | 49 | 46.3% |
| MOROCCO | $800.0K | 16 | 22.3% |
| SOUTH AFRICA | $400.0K | 8 | 11.2% |
| NEW ZEALAND | $322.2K | 9 | 9.0% |
| BELGIUM | $159.1K | 12 | 4.4% |
| VIETNAM, DEMOCRATIC REP. OF | $149.1K | 3 | 4.2% |
| AUSTRALIA | $50.0K | 1 | 1.4% |
| UNITED KINGDOM | $43.7K | 5 | 1.2% |
Cipla Limited exports Imatinib to 8 countries. The largest destination is PAKISTAN accounting for 46.3% of Cipla Limited's Imatinib shipments, followed by MOROCCO (22.3%) and SOUTH AFRICA (11.2%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Imatinib from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| COOPER PHARMA | MOROCCO | $800.0K | 16 |
| HABIB BANK LIMITED | PAKISTAN | $750.0K | 15 |
| JS BANK LTD. | PAKISTAN | $407.8K | 17 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $300.0K | 6 |
| TO THE ORDER OF JS BANK LTD | PAKISTAN | $239.9K | 6 |
| TO THE ORDER OF JS BANK LIMITED, | PAKISTAN | $142.3K | 6 |
| REX MEDICAL LTD | NEW ZEALAND | $135.6K | 4 |
| H.ESSERS & ZONEN INTERNATIONAL TRAN | BELGIUM | $103.3K | 6 |
| REX MEDICAL LTD, | NEW ZEALAND | $96.0K | 3 |
| REX MEDICAL LIMITED | NEW ZEALAND | $90.6K | 2 |
Cipla Limited supplies Imatinib to 21 buyers globally. The largest buyer is COOPER PHARMA (MOROCCO), followed by HABIB BANK LIMITED (PAKISTAN) and JS BANK LTD. (PAKISTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Imatinib Export Value and How Much Does Cipla Limited Contribute?
India exported $18.5M worth of Imatinib through 1,726 shipments from 224 suppliers to 119 countries, serving 456 buyers globally. Cipla Limited contributes $5.2M to this total, accounting for 17.6% of India's Imatinib exports. Cipla Limited ships Imatinib to 8 countries through 21 buyers.
What Is the Average Shipment Value for Cipla Limited's Imatinib Exports?
Cipla Limited's average Imatinib shipment value is $50.0K per consignment, based on 103 shipments totaling $5.2M. The largest destination is PAKISTAN (46.3% of Cipla Limited's Imatinib exports).
How Does Cipla Limited Compare to Other Indian Imatinib Exporters?
Cipla Limited ranks #1 among 224 Indian Imatinib exporters with a 17.6% market share. The top 3 exporters are CIPLA LIMITED ($5.2M), EUGIA PHARMA SPECIALITIES LIMITED ($4.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.9M). Cipla Limited processed 103 shipments to 8 destination countries.
What Imatinib Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| IMAVEC 400MG CAPSULLES (IMATINIB 400MG ) [3825(PACKS)X3X10'S]NOS | $300.0K | 6 |
| IMATINIB COOPER 100 MG CAPSULES ( IMATIN | $200.0K | 4 |
| IMATINIB COOPER 100 MG CAPSULES IMATIN | $150.0K | 3 |
| IMATIB ALPHA 100 CAPSULES ( IMATINIB CAPSULES 100 MG )(1X10'S X 60120 PACKS =601200 NOS)NOS | $150.0K | 3 |
| IMATINIB COOPER 100 MG CAPSULES (IMATINIB MESYLATE (ALPHA FORM) 100MG) [1133(PACKS)X10X10'S] | $150.0K | 3 |
| IMATINIB COOPER 100 MG CAPSULES (IMATINI | $100.0K | 2 |
| IMATINIB COOPER 100 MG CAPSULES ( IMATINIB MESYLATE (ALPHA FORM) 100 MG) (INV.QTY.1170 PACK 10X10S=117000 NOS) | $100.0K | 2 |
| IMATINIB ORION 100MG CAPSULES (IMATINIB100MG)PACK SIZE 12 X 10S | $76.4K | 3 |
| IMATINIB 100 MG CAPSULES INV QTY 1848 PACK 6X10S 110880 NOS | $75.0K | 2 |
| IMATIB ALPHA 100 CAPSULES ( IMATINIB CAPSULES 100 MG ) INV.QTY.23710 PACK 1X10'S=237100 NOS | $73.0K | 3 |
Cipla Limited exports 63 distinct Imatinib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is IMAVEC 400MG CAPSULLES (IMATINIB 400MG ) [3825(PACKS)X3X10'S with 6 shipments worth $300.0K.
Regulatory Requirements: Exporting Imatinib to Key Markets
What Cipla Limited must comply with to export Imatinib to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Imatinib Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $5.2M | 103 | 8 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $4.1M | 82 | 2 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $2.9M | 72 | 7 | $40.3K |
Cipla Limited ranks #1 among 224 Indian Imatinib exporters. Average shipment value of $50.0K compared to the market average of $82.5K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Imatinib Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 314 | 18.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 301 | 17.4% |
| DELHI AIR CARGO ACC (INDEL4) | 235 | 13.6% |
| DELHI AIR | 142 | 8.2% |
| Bombay Air | 123 | 7.1% |
| HYDERABAD AIR | 69 | 4.0% |
| HYDERABAD ACC (INHYD4) | 61 | 3.5% |
| AHEMDABAD AIR | 35 | 2.0% |
Geopolitical & Trade Policy Impact on Cipla Limited's Imatinib Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Imatinib, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Imatinib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Imatinib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 103 individual customs records matching Cipla Limited exporting Imatinib, covering 63 formulations to 8 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 119+ countries, 456+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Imatinib Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Imatinib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Imatinib Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Imatinib. For current shipment-level data, contact TransData Nexus.